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Abstract
Background: The extent and the distribution of end stage kidney disease (ESKD) in Libya have not been reported
despite provision of dialysis over 4 decades. This study aimed to develop the first comprehensive description of the
epidemiology of dialysis-treated ESKD in Libya.
Methods: Structured demographic and clinical data were obtained regarding all adult patients treated at all
maintenance dialysis facilities (n=39) in Libya from May to September 2009. Subsequently data were collected
prospectively on all new patients who started dialysis from September 2009 to August 2010. Population estimates
were obtained from the Libyan national statistics department. The age and gender breakdown of the population in
each region was obtained from mid-2009 population estimates based on 2006 census data.
Results: The prevalence of dialysis-treated ESKD was 624 per million population (pmp). 85% of prevalent patients
were aged <65 years and 58% were male. The prevalence of ESKD varied considerably with age with a peak at
55–64 years (2475 pmp for males; 2197 pmp for females). The annual incidence rate was 282 pmp with some
regional variation and a substantially higher rate in the South (617 pmp). The most common cause of ESKD among
prevalent and incident patients was diabetes. Other important causes were glomerulonephritis, hypertensive
nephropathy and congenital or hereditary diseases.
Conclusions: Libya has a relatively high prevalence and incidence of dialysis-treated ESKD. As the country prepares
to redevelop its healthcare system it is hoped that these data will guide strategies for the prevention of CKD and
planning for the provision of renal replacement therapy.
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Background
End-stage kidney disease (ESKD) is highly prevalent glo-
bally. It has become a major public health problem and
is associated with considerable co-morbidity and mortal-
ity. Maintenance dialysis therapy is the commonest
mode of renal replacement therapy and demand for this
service is increasing progressively worldwide.
Libya is a sparsely populated medium-developed coun-
try but it has a high prevalence of risk factors for
chronic kidney disease (CKD) such as diabetes, hyper-
tension and obesity [1-4]. Societal, economic and envir-
onmental transformation have contributed to people
tending to adopt a sedentary life [5]. Attention paid by
the primary health care systems to combat the rising
epidemic of chronic diseases has been inadequate [6]. In
contrast, Libya was among the first countries in the
region to establish free access to maintenance dialysis
therapy for patients with ESKD [7]. Health care adminis-
trative bodies have continued to expand dialysis services
in terms of geographic coverage and capacity to cope
with increasing demand [7]. Kidney transplantation in
Libya is limited by the lack of cadaveric donors and lim-
ited availability of suitable living-related donors [8,9].
Thus the majority of patients with ESKD remain dialysis
dependent. Nevertheless, data regarding the epidemi-
ology of ESKD and dialysis treatment in Libya are scarce
and knowledge about the spectrum of renal diseases is
very limited. The purpose of this study was to develop
the first comprehensive description of the epidemiology
of dialysis-treated ESKD in Libya. The study was per-
formed prior to the recent conflict but as Libya prepares
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to redevelop its healthcare system these data will be vital
to guide strategies for the prevention of CKD and plan-
ning for the provision of renal replacement therapy.
Results
Prevalence of ESKD in Libya
As shown in Table 1, the total number of adult ESKD
patients undergoing maintenance dialysis therapy in Libya
was 2417 in August 2009. The estimated adult population
of Libya during 2009 was 3,873,000, giving a prevalence
of dialysis-treated ESKD of approximately 624 per million
population (pmp). The prevalence rate varied slightly by
region with the highest rate of 628 pmp in North West
region, the most populated area of the country. Most
prevalent patients were under 65 years of age (85%).
Female patients tended to be older than males, except in
the South. Duration of dialysis was a median of 3 years
and tended to be lower in females (Table 2). The majority
of dialysis patients were Libyan nationals (97.8% of preva-
lent and 96.6% of incident patients).
Figure 1, shows that the prevalence of dialysis-treated
ESKD was higher among males versus females at all
ages. Overall, males represented 58% of prevalent dialy-
sis population. The prevalence of ESKD varied consider-
ably with age. Prevalence rates were low in young adults
but showed a steady increase with age. Prevalence rates
peaked in the 55–64 year age group at 2475 pmp for
males and 2197 pmp for females. After age 74 years
there was a sharp decline in prevalence and very few
patients were over 85 years. Most prevalent patients on
dialysis were white ethnicity (87%). However, ethnic dis-
tribution varied between regions with the highest black
to white ratio of 1.9 to 1 in the South.
Incidence of ESKD in Libya
A total of 1093 new patients started dialysis during the
1-year observation period, giving an incidence rate of
282 pmp. Incidence rates varied between regions with a
substantially higher rate observed in the South (Table 1).
In most age groups the incidence rate was higher in males
than females (Figure 2). The incidence rate increased with
age until it peaked in those aged 65–74 years and
decreased sharply beyond age 75 years. Incident female
patients were slightly older than male patients. Most inci-
dent patients on dialysis were white (80.9%).
Aetiology of ESKD in Libya
Information about primary kidney disease was complete
for all prevalent dialysis patients but was missing in 75
(6.9%) of incident dialysis patients. Data are shown in
Tables 3 and 4. The most common cause of ESKD
among prevalent and incident patients was diabetes. The
frequency of different categories of pathology was simi-
lar for prevalent and incident patients. Diabetes and
hypertensive nephropathy were more common as causes
of ESKD in patients aged 50 years or older whereas
glomerulonephritis and hereditary diseases were more
common in those aged under 50 years. Autoimmune
diseases accounted for only a small proportion of all
ESKD and were more common among females.
Discussion
This study represents the first comprehensive descrip-
tion of the epidemiology of dialysis-treated ESKD in
Table 1 Prevalent and Incident dialysis patient numbers










1558 653 206 2417
Prevalence rate 2009
(pmp)
628 623 597 624
Number of incident
patients 2010
593 287 213 1093
Incidence rate 2010
(pmp)
239 274 617 282
Table 2 Age, age at onset and dialysis vintage for
prevalent and incident dialysis patients in Libya and its












Age of prevalent Male 49 46 49 48
patients in years 36-61 35-59 36-61.3 36-61 49
(n=2417) Female 49 50.5 42.5 49 36-61
34-60 37-61 32.3-59 35-61
Age at onset
of dialysis
Male 45 42 47 44
(n=2417) 31-58 28-55 31-59.9 30-58 45
Female 45 46 38 45 30-58
30-57 31-57 27-57.8 30-57
Dialysis vintage
in years
Male 3 3 2 2.5
(n=2417) 1-6 1-7 0.1-4 1-6 3
Female 3 3 2 3 1-6
1-5 1-6 2-2 1-6
Age of incident
patients
Male 50 47 46 48
in years (n=1093) 37-63 34-61 30-57 35-61 49
Female 52 53 43 50 35-62
35-66 41-64 36-54 36-64
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Libya. Our study shows a prevalence rate for ESKD
markedly higher than rates estimated for the Mediterra-
nean region of 312 to 352 pmp [10,11] despite similar
demographic and socioeconomic characteristics between
Libya and neighbouring countries. Libya’s prevalence
rate is also higher than rates reported from individual
countries in the region like Saudi Arabia (475 pmp) [12],
El-Minia city in Egypt (208 pmp) [13], Kuwait
(240 pmp) [10] and Oman (220 pmp) [10]. Reasons for
the high prevalence rate in Libya might include a high
prevalence of CKD in the population and limited access
to renal transplantation [8,14]. The high incidence rate
of ESKD observed in this study (282 pmp) supports the
notion that CKD is an important health problem in
Libya that requires urgent attention. The rate is more
than double that observed in European countries such
as Austria (131 pmp) [15] and Denmark (129 pmp) [15]
despite the fact that the Libyan population is younger
than that of most European countries. Moreover, the
incidence rate observed in Libya is even higher than
rates reported in other places with young populations


















































Figure 2 Incidence rate pmp of dialysis-treated ESKD in Libya for males and females by age group.
Alashek et al. BMC Nephrology 2012, 13:33 Page 3 of 7
http://www.biomedcentral.com/1471-2369/13/33
Bhopal city in India (151 pmp) [18], Malaysia (138 pmp)
[19], Saudi Arabia (122 pmp) [12], Jordan (111 pmp)
[20] and Aleppo city in Syria (60 pmp) [21]. Whereas
the prevalence rate did not vary by much in the different
geographic regions of Libya the observed incidence rate
was substantially higher in the South. Regional variation
in incidence of ESKD has been reported by other
authors [22,23]. The reasons for this variation in Libya
require further investigation and have important impli-
cations for future healthcare provision. The South of
Libya is a remote, sparsely populated and deprived area.
It is also hot and dry and is inhabited by a mixture of
different minorities such as black Arabs, Tuareg and
Tebou tribes. Thus geographic, racial and socioeconomic
factors may all be relevant. It is also notable that the
proportion of new patients who commenced dialysis
therapy in one year represents 45% of the number of
prevalent dialysis patients in Libya. Moreover in the
South the incidence rate was triple the prevalence rate.
Possible explanations for these observations include a
high mortality rate on dialysis or rapidly increasing inci-
dence of ESKD. Both possibilities require urgent investi-
gation and have serious implications for future demand
for dialysis in Libya.
The median age of prevalent patients revealed by this
study was substantially lower than that observed in other
countries including the UK (65.9 years for haemodial-
ysis and 61.2 years for peritoneal dialysis) [24], USA
(59.1 years) [25], Iceland (64.4 years), Austria (60.1 years),
Denmark (58.8 years) and Greece (58.1 years) [15]. The
majority of patients with ESKD in Libya are of econom-
ically active age and ESKD therefore has a significant
impact on families and society. The observed median age
for incident patients in Libya (49 years) was considerably
lower than the UK (64.8 years) [26]. Consistent with
studies from most other countries, males outnumbered
Table 3 Aetiology of primary kidney disease of prevalent dialysis patients according to gender and age
Primary kidney disease Gender Age All patients
Male (n=1402) Female (n=1015) <50 years (n=1268) ≥50 years (n=1149) (n=2417)
Diabetic Nephropathy 396 (28.2)* 245 (24.1) 169 (13.3)* 472 (41.1) 641 (26.5)
Hypertensive Nephropathy 180 (12.8) * 173 (17) 129 (10.2)* 224 (19.5) 353 (14.6)
Glomerulonephritis 318 (22.7) * 194 (19.1) 413 (32.6)* 99 (8.6) 512 (21.2)
Interstitial Nephritis 14 (1) 15 (1.5) 17 (1.3) 12 (1) 29 (1.2)
Obstructive Nephritis 78 (5.6) 42 (4.1) 59 (4.7) 61 (5.3) 120 (5)
Chronic pyelonephritis 19 (1.4) * 29 (2.9) 33 (2.6) * 15 (1.3) 48 (2)
Polycystic kidney disease 82 (5.8) 70 (6.9) 68 (5.4) 84 (7.3) 152 (6.3)
Congenital and hereditary diseases 168 (12) * 130 (12.8) 220 (17.3)* 78 (6.8) 298 (12.3)
Autoimmune diseases 4 (0.3) * 13 (1.3) 16 (1.3) * 1 (0.1) 17 (0.7)
Other 39 (2.8) 32 (3.2) 48 (3.8) * 23 (2) 71 (2.9)
Unknown 104 (7.4) 72 (7.1) 96 (7.6) 80 (7) 176 (7.3)
Data are number (percent).
*P<0.05 versus comparitor group.
Table 4 Aetiology of primary kidney disease of incident dialysis patients according to gender and age
Primary Kidney Disease Gender Age All patients
Male (n=621) Female (n=397) <50 years (n=521) ≥50 years (n=497) (n=1018)
Diabetic Nephropathy 173 (27.9) 116 (29.2) 90 (17.3)* 199 (40) 289 (28.4)
Hypertensive Nephropathy 101 (16.3) 60 (15.1) 29 (5.6)* 132 (26.6) 161 (15.8)
Glomerulonephritis 133 (21.4) 71 (17.9) 173(33.2)* 31 (6.2) 204 (20)
Interstitial Nephritis 7 (1.1)* 17 (4.3) 14 (2.7) 10 (2) 24 (2.4)
Obstructive Nephritis 53 (8.5)* 6 (1.5) 17 (3.3)* 42 (8.5) 59 (5.8)
Chronic pyelonephritis 9 (1.4) 4 (1) 0 (0)* 13 (2.6) 13 (1.3)
Polycystic kidney disease 13 (2.1)* 41 (10.3) 31 (6) 23 (4.6) 54 (5.3)
Congenital and hereditary diseases 42 (6.8) 40 (10.1) 73 (14)* 9 (1.8) 82 (8.1)
Autoimmune diseases 4 (0.6)* 10 (2.5) 11 (2.1)* 3 (0.6) 14 (1.4)
Other 10 (1.6) 4 (1) 10 (1.9) 4 (0.8) 14 (1.4)
Unknown 76 (12.2)* 28 (7.1) 73 (14)* 31 (6.2) 104 (10.2)
Data are number (percent).
*P<0.05 versus comparitor group.
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females in the prevalent and incident populations
[25,27,28]. Nevertheless, the median age of incident
females in the South was a decade younger than females
in other regions of the country. This wide range of age
presentation in the South might reflect gender inequity,
health care deficiency and environmental factors.
Like many other countries diabetic nephropathy was
the leading causes of ESKD in both prevalent and inci-
dent dialysis populations and was significantly more
common among older patients. Generally, the preva-
lence of diabetes in Middle East region is high according
to the International Diabetes Federation [29,30]. Reasons
include increasing urbanisation, aging of the population,
increasing obesity and falling levels of physical activity
[31,32]. Efforts to reduce the burden of ESKD in Libya
should therefore focus on measures to reduce incidence
of type 2 diabetes mellitus [33,34] through public aware-
ness, screening and promotion of a healthy lifestyle as
well as prevention of microvascular complications in
those with diabetes [35]. Glomerulonephritis was the
second most frequent cause of ESKD in Libya in preva-
lent and incident cases and was significantly more com-
mon among young and male patients. The observed
proportion is midway between very high levels reported
from countries like China and Kuwait of approximately
35% [36,37], Costa Rica (30%) [38] and Yemen (25%)
[39] and lower prevalence observed in countries like
Qatar (13%) [16], Sri Lanka (12%) [40] and Pakistan
(10%) [41]. Reasons for the high prevalence of glomer-
ulonephritis require further investigation, which is ham-
pered by the shortage of facilities able to perform renal
biopsies and histology. A substantial proportion of ESKD
was attributed to hypertension but it is unclear what
proportion of this represented hypertension secondary
to primary renal disease. Congenital and hereditary kid-
ney disease accounted for a significant minority of ESKD
in both prevalent and incident patients. This is likely
due to the high rate of marriages between relatives,
especially first cousins, in Arab communities [42-44]
including Libya. A shortage of genetic diagnostics and
counselling is a major contributor to this problem. In
summary, despite Libya’s unique social and demographic
features the observed causes of ESKD are similar to that
described in most other countries, though the contribu-
tion of glomerulonephritis and hereditary kidney disease
is greater than in many developed countries. It is there-
fore likely that interventions that have proved successful
in reducing the incidence of ESKD in other countries
such as early detection of CKD, treatment of hyperten-
sion with angiotensin-converting enzyme inhibitors and
prevention or treatment of diabetes are likely to be
effective in Libya too.
Strengths of this study are the inclusion of all current
dialysis units in the country to ensure collection of the
most complete data possible and prospective capture
of data regarding new patients commencing dialysis.
Limitations include reliance on limited and partially
incomplete medical records and lack of histology to
confirm the cause of ESKD in the majority of cases. We
have described the epidemiology of ESKD among
patients receiving dialysis but there are no data regard-
ing patients with ESKD who died without the benefit of
dialysis. It is therefore likely that the true incidence of
ESKD is higher than what we have observed. Further
research is required to investigate how many patients with
ESKD are not offered dialysis and the reasons for this.
Conclusions
In conclusion we report for the first time high preva-
lence and incidence rates of dialysis-treated ESKD in
Libya. The relatively young age of those affected empha-
sizes the need for urgent measures to reduce the inci-
dence of CKD and its progression. Emphasis should be
placed in the first instance on the prevention and treat-
ment of diabetes and hypertension. Further research is
required to investigate the high incidence of glomerulo-
nephritis. As Libya rebuilds its healthcare system follow-
ing the recent conflict it is hoped that the prevention of
ESKD will constitute an important priority and that the
data presented will inform the strategies required.
Methods
The study was performed by a Libyan researcher with
support and guidance provided by a Nephrology Depart-
ment in the United Kingdom. First, a cross-sectional
study was performed from May to September 2009. This
included all adult maintenance dialysis facilities in Libya
(n=39), which all belong to the public sector. Medical
supervisors of maintenance dialysis facilities throughout
the country were contacted by visit or phone call to be
informed about the study. All agreed to participate and
to cooperate with the research team.
A data collection sheet was prepared and used to gather
information about all currently registered dialysis patients
in the country. Forms included data regarding date of
birth, sex, ethnicity, nationality, type of dialysis, date of dia-
lysis initiation and primary kidney disease. Date of birth
was recorded if known. Otherwise, the year of birth was
used. The same applied for the date of first dialysis. Pri-
mary kidney disease was recorded according to the opinion
of the treating physician or medical reports when available.
For the majority of dialysis units (n=28), the research team
collected all information by interviewing patients and
inspecting medical records to assure quality and validity of
the data. For remote facilities, data collection sheets were
distributed to the clinical supervisor for completion. Fre-
quent phone calls were used to answer queries and ensure
that data were correctly documented. A pilot study was
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undertaken in 5 dialysis units that included 100 patients (20
from each unit). Difficulties in collecting data were explored
and solutions developed. Data were cross checked for
patients who were known to receiving dialysis in another
centre within the country. Patients who were absent at the
time of the study for a period of less than one month for
travel in or outside the country were included among the
prevalent population. Analyses performed included all adult
patients prevalent on dialysis on 30 August 2009.
Population estimates were obtained from the Libyan
national statistics department. The age and gender
breakdown of the population in each region was
obtained from mid-2009 population estimates based on
2006 census data. The number of dialysis patients was
calculated for the country as a whole. In order to investi-
gate geographic variation in the epidemiology of ESKD,
data were also grouped into 3 main geographic regions.
The second stage of the study was a prospective col-
lection of information about all new patients who started
dialysis from September 2009 to August 2010. Variables
collected were identical to that used during the cross-
sectional study and the same data forms were used. The
research team conducted data collection frequently dur-
ing the year to ensure the inclusion of every new patient
in the country. Subsequently, researchers conducted
field visits to dialysis facilities from September to
December 2010 to validate the information.
Data are presented as mean±standard deviation if nor-
mally distributed or median (interquartile range) if not.
A Chi-squared test was used to compare frequencies
between groups. A p-value of <0.05 was considered
statistically significant. Analysis was performed by using
SPSS version 16.0.
Permission to conduct the study was granted by the
Ministry of Health. Ethical approval for the research was
obtained from the Libyan National Committee for Bio-
ethics and Bio-safety. Patients each gave written
informed consent.
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